3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Recruiting
3
Sponsor Class
OTHER
3
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
3
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
2
Waldenstrom Macroglobulinemia
1
Lymphoma, Non-Hodgkin
1
Leukemia, B-Cell
1
Hematologic Neoplasms
1
Interventions
pembrolizumab
131
Carboplatin
106
Paclitaxel
66
Cisplatin
61
Gemcitabine
57
Pemetrexed
56
Bevacizumab
50
Docetaxel
47
Fluorouracil
40
Oxaliplatin
38
Dexamethasone
34
130-nm albumin-bound paclitaxel
34
Leucovorin
33
atezolizumab
32
Cetuximab
32
durvalumab
30
Nivolumab
28
Rituximab
26
Cyclophosphamide
26
Capecitabine
26
Prednisone
25
Fulvestrant
24
enzalutamide
23
Lenalidomide
22
venetoclax
21
Letrozole
20
Irinotecan
20
Doxorubicin
17
ribociclib
16
pomalidomide
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
ARQ531
×
30 days
×
Clear all
NCT06136559
2026-05-28
BELLWAVE-011
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,200 enrolled
NCT04728893
2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2
Recruiting
490 enrolled
NCT05947851
2026-05-18
BELLWAVE-010
Merck Sharp & Dohme LLC
Phase 3
Recruiting
735 enrolled